The pharmacokinetics of a new 10 mg sublingual tablet formulation of temazepam and those of a currently marketed 10 mg oral capsule formulation were evaluated in a group of ten healthy volunteers.
No significant differences were observed between the two formulations with respect to any of the pharmacokinetic parameters assessed. Lethargy and somnolence were reported on both capsule and tablet by several subjects at a time which corresponded with the maximum concentration of drug in plasma.
The data indicate that the sublingual tablet and orally administered capsule have a similar pharmacokinetic and pharmacodynamic profile.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Badcock NR, Pollard AC (1982) Micro-determination of clonazepam in plasma or serum by electron-capture gas-liquid chromatography. J Chromatogr 230: 353–361
Bolton S (1984) Pharmaceutical statistics. Marcel Dekker, New York
Ghabrial H, Desmond PV, Watson KJR, Gijsbers AJ, Harman PJ, Breen KJ, Mashford ML (1986) The effects of age and chronic liver disease on the elimination of temazepam. Eur J Clin Pharmacol 30: 93–97
About this article
Cite this article
Russell, W.J., Badcock, N.R., Frewin, D.B. et al. Pharmacokinetics of a new sublingual formulation of temazepam. Eur J Clin Pharmacol 35, 437–439 (1988). https://doi.org/10.1007/BF00561380